Non-Hodgkin Lymphoma - Pipeline Review, Q4 2010

Global Markets Direct, December 2010, Pages: 216

Non-Hodgkin Lymphoma - Pipeline Review, Q4 2010

Summary

Global Markets Direct’s, “Non-Hodgkin Lymphoma Pipeline Review, Q4 2010”, provides an overview of the Non-Hodgkin Lymphoma therapeutic pipeline. This report provides information on the therapeutic development for Non-Hodgkin Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Non-Hodgkin Lymphoma. “Non-Hodgkin Lymphoma-Pipeline Review 2010, Q4 2010” is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- A snapshot of the global therapeutic scenario for Non-Hodgkin Lymphoma.
- A review of the Non-Hodgkin Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Non-Hodgkin Lymphoma pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Non-Hodgkin Lymphoma.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Non-Hodgkin Lymphoma pipeline depth and focus of Non-Hodgkin Lymphoma therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Content
s

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Non-Hodgkin Lymphoma Overview
An Overview of Pipeline Products for Non-Hodgkin Lymphoma
Non-Hodgkin Lymphoma Therapeutics under Development by Companies
Non-Hodgkin Lymphoma Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Companies Involved in Non-Hodgkin Lymphoma Therapeutics Development
Bristol-Myers Squibb Company
Genzyme Corporation
Johnson & Johnson
F. Hoffmann-La Roche Ltd.
Biogen Idec Inc.
Amgen Inc.
Sanofi-Aventis
Eli Lilly and Company
GlaxoSmithKline plc
Seattle Genetics, Inc.
Biotec Pharmacon ASA
Gilead Sciences, Inc.
Merck & Co., Inc.
Emergent BioSolutions Inc.
Micromet, Inc.
Takeda Pharmaceutical Company Limited
ZIOPHARM Oncology, Inc.
Millennium Pharmaceuticals, Inc.
Novartis AG
Astellas Pharma Inc.
Cephalon, Inc.
Genta Incorporated
Human Genome Sciences, Inc.
Pfizer Inc.
Cell Therapeutics, Inc.
Genmab A/S
Astex Therapeutics Limited
Celgene Corporation
Onyx Pharmaceuticals, Inc.
Bayer AG
Hana Biosciences, Inc.
Genitope Corporation
IMMUNOMEDICS, INC
InNexus Biotechnology Inc.
MethylGene Inc
Compugen Ltd.
Portola Pharmaceuticals, Inc.
Cytokinetics, Inc
Pharmacyclics, Inc.
Dendreon Corporation
MorphoSys AG
Lipoxen PLC
Innate Pharma SA
SymBio Pharmaceuticals Limited
Arthur G. James Cancer Hospital & Richard J. Solove Research Institute
Kantonsspital Aarau AG
Asan Medical Center
Spectrum Pharmaceuticals, Inc.
The University of Chicago
Affimed Therapeutics AG
Memgen, LLC.
Abiogen Pharma S.p.A.
Calistoga Pharmaceuticals, Inc.
Onconova Therapeutics, Inc
Gemin X Pharmaceuticals
TaiGen Biotechnology Co., Ltd.
Mayo Clinic
Theradex Systems, Inc.
Hoosier Oncology Group, Inc.
Universities/Institutes Involved in Non-Hodgkin Lymphoma Therapeutics Development
Non-Hodgkin Lymphoma Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Companies
Arzerra - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cyclophosphamide + Prednisone + Vincristine sulfate + MyVax + Sargramostim - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MAbThera - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pixantrone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Revlimid - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RO5072759 + Bendamustine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SyB L-0501 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Late Stage Drug Profiles – Universities/Institutes
aldesleukin + filgrastim + cyclophosphamide + etoposide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
asparaginase + cyclophosphamide + cytarabine + daunorubicin hydrochloride + dexamethasone + doxorubicin hydrochloride + etoposide + leucovorin calcium + mercaptopurine + methotrexate + methylprednisolone + mitoxantrone hydrochloride + prednisolone + thera - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bendamustine + Rituximab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bleomycin Sulfate + Cyclophosphamide + Doxorubicin Hydrochloride + Etoposide + Prednisolone + Autologous Bone Marrow Transplantation + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
carmustine + cyclophosphamide + cytarabine + doxorubicin + etoposide + melphalan + prednisone + vincristine + stem cell transplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
carmustine + cyclophosphamide + etoposide + filgrastim + fludarabine + methotrexate + rituximab + tacrolimus + radiation therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CHEOP + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Chlorambucil + Dexamethasone + Idarubicin + Recombinant Interferon Alfa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Chlorambucil + Dexamethasone + Interferon alfa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Chlorambucil + Dexamethasone + Recombinant Interferon Alfa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Chlorambucil + Idarubicin + Dexamethasone + Interferon alfa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CHOP Regimen - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CHOP Regimen + Filgrastim + Cytarabine + Etoposide + Leucovorin Calcium + Melphalan + Methotrexate + Methylprednisolone + Mitoxantrone Hydrochloride + Hydrocortisone + Autologous Stem Cell Transplantation + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cisplatin + Dexamethasone + Gemcitabine + Rituximab + Autologus Stem Cell Transplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
cyclophosphamide + doxorubicin hydrochloride + prednisolone + vincristine sulfate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cyclophosphamide + Doxorubicin Hydrochloride + Prednisone + Vincristine Sulfate + Filgrastim - Drug Profile
Product Description
Mechanism of Action
R&D Progress
cyclophosphamide + mitoxantrone hydrochloride + prednisolone + vincristine sulfate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
cyclophosphamide + prednisone + vincristine sulfate + rituximab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
dexamethasone + cisplatin + cytarabine + etoposide + ifosfamide + methotrexate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dexamethasone + Cisplatin + Cytarabine + Etoposide + Ifosfamide + Methotrexate + Rituximab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Epratuzumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
filgrastim + recombinant interferon alfa + cyclophosphamide + prednisone + vincristine sulfate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
filgrastim + rituximab + carboplatin + etoposide + ifosfamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
filgrastim + rituximab + carboplatin + etoposide + ifosfamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
filgrastim + rituximab + CHOP regimen + cyclophosphamide + doxorubicin hydrochloride + prednisone + vincristine sulfate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Filgrastim + Rituximab + Sargramostim + CHOP regimen + Carmustine + Cyclophosphamide + Doxorubicin hydrochloride + Etoposide + Prednisone + Vincristine sulfate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Filgrastim + Rituximab + Sargramostim + CHOP regimen + Carmustine + Cyclophosphamide + Doxorubicin hydrochloride + Etoposide + Prednisone + Vincristine sulfate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fludarabine + Total Body Irradiation + Allogeneic Hematopoietic Stem Cell Transplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fludarabine + Total Body Irradiation + Recipient Leukocyte Infusion + Nonmyeloablative Allogeneic Stem Cell Transplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ibritumomab tiuxetan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Interferon Alfa-2b - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Mega-CHOEP + Rituximab + Autologous Stem Cell Transplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ONTAK - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pixantrone dimaleate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PMitCEBO - Drug Profile
Product Description
Mechanism of Action
R&D Progress
R-CHOP + Filgrastim - Drug Profile
Product Description
Mechanism of Action
R&D Progress
R-CHOP14 + Darbepoetin alfa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rituxan + CHOP Chemotherapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rituxan + Fludarabine + Cyclophosphamide + Tacrolimus + Methotrexate + Hematopoietic Stem Cell Transplant - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rituximab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rituximab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rituximab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rituximab + cisplatin + cytarabine + dexamethasone + gemcitabine hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rituximab-HDS - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Total Body Irradiation + Recipient Leukocyte Infusion + Nonmyeloablative Allogeneic Stem Cell Transplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Discontinued Products
Non-Hodgkin Lymphoma - Featured News
Dec 07, 2010: Micromet's Blinatumomab Produces High Objective Response Rate In Spectrum Of Relapsed Non-Hodgkin's Lymphoma Patients
Dec 07, 2010: Seattle Genetics And Millennium Present Positive Phase II Trial Data Of Brentuximab Vedotin In Relapsed Or Refractory ALCL At ASH Annual Meeting
Dec 06, 2010: Biovest Reports Updated Phase III Data Analysis For BiovaxID In Lymphoma
Dec 06, 2010: CTI Presents Pixantrone Phase III Follow Up Results At American Society Of Hematology Conference
Dec 06, 2010: Roche Presents New Phase II Data Of GA101 At American Society Of Hematology
Dec 03, 2010: Cell Therapeutics Files Appeal On FDA Decision On Pixantrone NDA To Treat Non-Hodgkin's Lymphoma
Dec 01, 2010: Cell Therapeutics To Present Pixantrone Phase III Study Results At Annual Meeting Of American Society Of Hematology
Nov 18, 2010: Cell Therapeutics Receives European Acceptance Of Pixuvri MAA
Nov 10, 2010: Cyclacel Announces Publication Of Preclinical Data Of Sapacitabine With Targeted Agents For Treatment Of Cancer
Nov 09, 2010: Micromet To Provide Update On BiTE Antibody R&D Programs At 2010 American Society Of Hematology Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Customers who bought this item also bought

• Substance (Drug) Abuse – Pipeline Review, H1 2013
• Pandemic Influenza – Pipeline Review, H1 2013
• Drug Addiction – Pipeline Review, H1 2013
• Oncology Intelligence: A Comprehensive Report for Decision Making
• Ebola Viral Infections – Pipeline Review, H1 2013
• Bone Disorders – Pipeline Review, H1 2013
• Brain Tumor – Pipeline Review, H1 2013
• Natural Killer Cell Lymphomas – Pipeline Review, H1 2013
• Smoking Cessation – Pipeline Review, H1 2013
• Nausea – Pipeline Review, H1 2013